The late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), announced today the appointment of Sally Lawlor, BCL, FCA, as Chief Financial Officer. The leadership change comes as the company advances its lead candidate, QRX003, through pivotal studies and prepares for potential commercialization.
Lawlor brings more than two decades of financial leadership experience across public and private companies as well as a Big Four accounting firm. Most recently, she served as Vice President of Finance at Sebela Pharmaceuticals, where she oversaw financial reporting under U.S. GAAP and IFRS, managed global tax planning and compliance, and directed budgeting, forecasting, and external audits. Her prior roles include senior tax leadership at Aptiv Plc and more than a decade advising multinational pharmaceutical and technology clients at KPMG. She is a Fellow of Chartered Accountants Ireland and a member of the Irish Taxation Institute.
“As we move closer to completing our QRX003 registrational trials in Netherton Syndrome and prepare for a potential NDA filing next year, we are aligning our leadership structure to support the next phase of Quoin’s growth,” said Dr. Michael Myers, Chief Executive Officer of Quoin. “We are thrilled to welcome Sally as Chief Financial Officer. She has extensive experience in commercial-stage finance, global tax strategy design and implementation, as well as multinational compliance, which we believe makes her exceptionally qualified to guide Quoin through our transition into a revenue-generating company. Sally adds invaluable expertise to our executive team at this pivotal time. I also want to thank Gordon Dunn for his dedicated contribution during his tenure as Quoin’s CFO. We wish him all the best in his future endeavors.”
Quoin is currently conducting two pivotal clinical trials of QRX003 for Netherton Syndrome at sites in the U.S., Europe, and the Middle East, with full enrollment expected in early to mid-Q1 2026. The company is also progressing development programs for Peeling Skin Syndrome and advancing a novel topical rapamycin platform targeting rare dermatologic conditions.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, microcystic lymphatic malformations, venous malformations, angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
This article contains sponsored content. Please see our disclaimer at: https://prismmarketview.com/disclaimer/
The post Quoin Pharmaceuticals Appoints Sally Lawlor as CFO to Support Commercialization Strategy appeared first on PRISM MarketView.